Genetic basis for clinical response to CTLA-4 blockade in melanoma.

By A. Snyder, V. Makarov, T. Merghoub, Jianda Yuan, J. Zaretsky, A. Desrichard, L. Walsh, M. Postow, P. Wong, Teresa Ho and 11 more. New England Journal of Medicine, 2014

3,876 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/c8ed028333d7fb2fa4826998155936050f9faba6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. James P. Allison
2. J. Wolchok
3. S. Shalapour
4. Padmanee Sharma
5. M. Karin
6. D. Pardoll
7. Zena Werb
8. S. Topalian

In Molecular Biology

1. S. Baylin
2. Peter W. Laird
3. Eric S. Lander
4. Zena Werb
5. Manel Esteller
6. Feng Zhang
7. Nicholas McGranahan
8. Charles Swanton

In Oncology

1. J. Wolchok
2. James P. Allison
3. D. Pardoll
4. Padmanee Sharma
5. Charles Swanton
6. Nicholas McGranahan
7. F. Hodi
8. Zena Werb

Citations in the corpus

• Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer (2016, background): “cancer (NSCLC) (4) and melanoma (5, 6) suggesting that a high density of neoepitopes stemming from somatic mutations may enhance clinical benefit from blockade of immune checkpoints that unleash endogenous responses to these mutation-associated neoantigens (MANAs).”
• Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016, background): “Preliminary evidence emerging from clinical trials of immune checkpoint blockade therapy suggests that high mutation burdens may be predictive of good responses in NSCLC and melanoma [10, 11].”